当前位置: X-MOL 学术Am. J. Clin. Oncol. › 论文详情
Our official English website, www.x-mol.net, welcomes your feedback! (Note: you will need to create a separate account there.)
Prognostic Factors of Second-line Immune Checkpoint Inhibitors in Patients With Advanced-stage Non-Small Cell Lung Cancer: A Multicenter, Retrospective Study.
American Journal of Clinical Oncology ( IF 1.6 ) Pub Date : 2021-05-17 , DOI: 10.1097/coc.0000000000000828
Jiyeon Roh 1 , Jung Seop Eom 1 , Min Ki Lee 1 , Jehun Kim 2 , Taewon Jang 2 , Seong Hoon Yoon 3 , Choon-Hee Son 4 , Hyun-Kyung Lee 5 , Hyun-Kuk Kim 6 , Shin Yup Lee 7 , Kyeong Choel Shin 8 , Mi-Hyun Kim 1
Affiliation  

Immune checkpoint inhibitors (ICIs) targeting the programmed cell death receptor-1 and its ligand have achieved impressive success in treating patients with advanced-stage non-small cell lung cancer (NSCLC) after failed first-line cytotoxic chemotherapy. However, knowledge on clinical biomarkers that could help select patients who will respond well to second-line ICI therapy is limited.

中文翻译:

晚期非小细胞肺癌患者二线免疫检查点抑制剂的预后因素:一项多中心、回顾性研究。

针对程序性细胞死亡受体-1 及其配体的免疫检查点抑制剂 (ICI) 在一线细胞毒性化疗失败后治疗晚期非小细胞肺癌 (NSCLC) 患者方面取得了令人瞩目的成功。然而,关于可以帮助选择对二线 ICI 治疗反应良好的患者的临床生物标志物的知识是有限的。
更新日期:2021-05-23
down
wechat
bug